Camizestrant as an add-on to palbociclib and abemaciclib for untreated hormone receptor-positive HER2-negative metastatic breast cancer with an ESR1 mutation [ID6535]

• Awaiting development
• Reference number: GID-TA11687
• Expected publication date: TBC